Additional file 3: Table S1-S6.

Overview of serious adverse events and adverse events of interest (E (E/100 PYs)) in patients who recieved no concomitant disease-modifying anti-rheumatic drugs (DMARDs), at least 1 concomitant DMARD, no concomitant corticosteriods, concomitant corticosteriods, no prior infliximab or etanercept, and prior infliximab or etanercept, respectively. E, events; PYs, patient-years.

Format: DOCX Size: 31KB Download file

Burmester et al. Arthritis Research & Therapy 2014 16:R24   doi:10.1186/ar4452